ASH 2019: J&J steals a march on anti-BCMA rivals
At this year’s annual meeting of the American Society of Hematology (ASH), Johnson & Johnson (NYSE: JNJ) has impressed with the first clinical data from its anti-BCMA CAR-T program, as rival candidates jostle for the lead in this area of innovation.
J&J presented data from the Phase Ib/II CARTITUDE-1 study of JNJ-4528 in people with relapsed or refractory multiple myeloma.
The heavily pre-treated patients in the test showed early and deep responses, with 100% showing a response at a median follow-up of six months. The overall response rate (ORR) included 69% of patients achieving a complete response (CR) or better.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze